Edith Rodríguez-Braun

Santa Lucía University General Hospital — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index1.0kcitations63works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(16), Colorectal Cancer Treatments and Studies(14), Growth Hormone and Insulin-like Growth Factors(9), Genetic factors in colorectal cancer(9), Cancer, Hypoxia, and Metabolism(7)

Publications63 total

Clinical and immunopathological evaluation and its comparison with IHC consensus molecular subtypes of colorectal cancer
Scientific Reports·2025· 2 citedOpen Access
Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial
Frontiers in Oncology·2023· 11 citedOpen Access
Data from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 3 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 3 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Data from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Andrés Cervantes(28), Susana Roselló(23), José García‐Solano(21), Josep Tabernero(21), Pablo Conesa‐Zamora(21), Anne Tuomisto(17), Markus J. Mäkinen(17), Fernando Pérez-Sánz(15), Begoña Alburquerque-González(15), María Antonia Parreño-González(15), Jesualdo Tomás Fernández‐Breis(15), Paola Pimentel(15), Ondřej Slabý(15), Teresa Macarulla(13), María Del Carmen Legaz-García(13), Ángel Esteban-Gil(12), José Baselga(8), Francesco Atzori(7), Ludmila Prudkin(7), Jordi Andreu(7)